Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.58
-0.03-1.55%
At close: -
$1.62
0.032.18%
After Hours: 7:59 PM EDT
Comments
Loading...
Gain Therapeutics Analyst Ratings and Price Targets | NASDAQ:GANX | Benzinga
Gain Therapeutics Inc has a consensus price target of $8.33 based on the ratings of 9 analysts. The high is $12 issued by Scotiabank on March 7, 2025. The low is $5 issued by B. Riley Securities on August 19, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Chardan Capital on July 3, 2025, May 19, 2025, and March 28, 2025, respectively. With an average price target of $7.33 between HC Wainwright & Co., HC Wainwright & Co., and Chardan Capital, there's an implied 352.81% upside for Gain Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Chardan Capital
Scotiabank
Roth MKM
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Gain Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
07/03/2025 | 393.98% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
05/19/2025 | 393.98% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
03/28/2025 | 270.48% | Chardan Capital | $6 → $6 | Maintains | Buy | |||
03/17/2025 | 393.98% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
03/07/2025 | 640.97% | Scotiabank | → $12 | Initiates | → Sector Outperform | |||
12/24/2024 | 332.23% | Roth MKM | $7 → $7 | Maintains | Buy | |||
12/05/2024 | 332.23% | Roth MKM | → $7 | Initiates | → Buy | |||
11/25/2024 | 393.98% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
10/09/2024 | 393.98% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
10/01/2024 | 393.98% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
09/03/2024 | 393.98% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
08/14/2024 | 393.98% | Oppenheimer | → $8 | Assumes | → Outperform | |||
08/09/2024 | 270.48% | Chardan Capital | $6 → $6 | Maintains | Buy | |||
07/11/2024 | 393.98% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
07/02/2024 | 393.98% | HC Wainwright & Co. | $9 → $8 | Maintains | Buy | |||
05/31/2024 | 455.73% | HC Wainwright & Co. | $9 → $9 | Reiterates | Buy → Buy | |||
05/28/2024 | 455.73% | HC Wainwright & Co. | $9 → $9 | Reiterates | Buy → Buy | |||
05/15/2024 | 455.73% | HC Wainwright & Co. | $9 → $9 | Reiterates | Buy → Buy | |||
04/25/2024 | 455.73% | HC Wainwright & Co. | $9 → $9 | Reiterates | Buy → Buy | |||
04/23/2024 | 455.73% | Oppenheimer | → $9 | Maintains | Outperform | |||
04/01/2024 | 455.73% | HC Wainwright & Co. | $9 → $9 | Reiterates | Buy → Buy | |||
03/27/2024 | 270.48% | Chardan Capital | → $6 | Reiterates | Buy → Buy | |||
12/04/2023 | 455.73% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy | |||
09/18/2023 | 517.47% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy | |||
09/12/2023 | 517.47% | Maxim Group | → $10 | Initiates | → Buy | |||
08/31/2023 | 517.47% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy | |||
08/14/2023 | 270.48% | Chardan Capital | → $6 | Reiterates | Buy → Buy | |||
08/14/2023 | 517.47% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy | |||
06/12/2023 | 517.47% | Oppenheimer | → $10 | Reiterates | Outperform → Outperform | |||
05/15/2023 | 517.47% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy | |||
05/15/2023 | 270.48% | Chardan Capital | $5.75 → $6 | Maintains | Buy | |||
05/01/2023 | 517.47% | HC Wainwright & Co. | → $10 | Reiterates | → Buy | |||
03/27/2023 | 255.05% | Chardan Capital | $4 → $5.75 | Maintains | Buy | |||
12/09/2022 | 146.99% | Chardan Capital | → $4 | Initiates | → Buy | |||
11/25/2022 | 517.47% | Oppenheimer | $30 → $10 | Maintains | Outperform | |||
11/14/2022 | 517.47% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy | |||
11/14/2022 | 517.47% | BTIG | $30 → $10 | Maintains | Buy | |||
08/19/2022 | 208.74% | B. Riley Securities | $11 → $5 | Downgrade | Buy → Neutral |
FAQ
What is the target price for Gain Therapeutics (GANX) stock?
The latest price target for Gain Therapeutics (NASDAQ:GANX) was reported by HC Wainwright & Co. on July 3, 2025. The analyst firm set a price target for $8.00 expecting GANX to rise to within 12 months (a possible 393.98% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gain Therapeutics (GANX)?
The latest analyst rating for Gain Therapeutics (NASDAQ:GANX) was provided by HC Wainwright & Co., and Gain Therapeutics reiterated their buy rating.
When was the last upgrade for Gain Therapeutics (GANX)?
There is no last upgrade for Gain Therapeutics
When was the last downgrade for Gain Therapeutics (GANX)?
The last downgrade for Gain Therapeutics Inc happened on August 19, 2022 when B. Riley Securities changed their price target from $11 to $5 for Gain Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Gain Therapeutics (GANX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on July 3, 2025 so you should expect the next rating to be made available sometime around July 3, 2026.
Is the Analyst Rating Gain Therapeutics (GANX) correct?
While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a reiterated with a price target of $8.00 to $8.00. The current price Gain Therapeutics (GANX) is trading at is $1.62, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
